Covid-19 roundup: Cit­ing a lack of need, Gilead cuts remde­sivir study; No­vavax vac­cine pro­duc­tion slowed due to sup­ply short­ages

Gilead is halt­ing its remde­sivir study in high-risk, non-hos­pi­tal­ized Covid-19 pa­tients af­ter a de­ci­sion that the study no longer ad­dress­es an un­met need, a state­ment said.

The study’s stop­page is not due to ef­fi­ca­cy or safe­ty con­cerns, the com­pa­ny stat­ed.

“While COVID-19 con­tin­ues to im­pact many pa­tients and their loved ones, un­met med­ical needs have evolved over the course of the pan­dem­ic. The pri­ma­ry un­met need for non-hos­pi­tal­ized pa­tients with COVID-19 is for ef­fec­tive and con­ve­nient ther­a­pies that can be eas­i­ly ad­min­is­tered at home. Gilead re­mains com­mit­ted to de­vel­op­ing treat­ment op­tions for non-hos­pi­tal­ized pa­tients with COVID-19 that ad­dress this need,” a state­ment says.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER